Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Geron Corporation    GERN   US3741631036

GERON CORPORATION (GERN)

18
Delayed Quote. Delayed Nasdaq - 01/30 04:00:03 pm
3.18 USD   -1.55%
2014 GERON : reports 3Q loss
2014 GERON : Announces Early HSR Clearance for Global Strategic Collabora..
2014 GERON : to Host Analyst and Investor Meeting on December 8
 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/26/2015 01/27/2015 01/28/2015 01/29/2015 01/30/2015 Date
3.32(c) 3.37(c) 3.28(c) 3.23(c) 3.18(c) Last
2 160 174 2 069 914 1 934 895 2 293 045 2 080 544 Volume
+2.79% +1.51% -2.67% -1.52% -1.55% Change
More quotes
Company
Geron Corp. discovers and develops therapeutic products for cancer.It is a clinical stage biopharmaceutical company developing a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.The company's imetelstat, their sole product candidate, is a potent and specific inhibitor of... 
Sector
Biotechnology & Medical Research
Calendar
02/09 | 02:00pmPresentation
More about the company
Surperformance© ratings of Geron Corporation
Trading Rating : Investor Rating :
More Ratings
Chart GERON CORPORATION
Duration : Period :
Geron Corporation Technical Analysis Chart | GERN | US3741631036 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 36,3 M
EBIT 2014 -13,6 M
Net income 2014 -12,9 M
Debt 2014 -
Yield 2014 -
Sales 2015 1,38 M
EBIT 2015 -43,6 M
Net income 2015 -43,5 M
Debt 2015 -
Yield 2015 -
PER 2014 -
PER 2015
Capi. / Sales 2014 14,0x
Capi. / Sales 2015 368x
Capitalization 508 M
More Financials
Latest news on GERON CORPORATION
01/12 GERON : Results of Operations and Financial Condition, Regulation FD Disclosure,..
2014 GERON : reports 3Q loss
2014 GERON : Other Events, Financial Statements and Exhibits (form 8-K)
2014 GERON : Announces Early HSR Clearance for Global Strategic Collaboration with Ja..
2014 GERON : to Host Analyst and Investor Meeting on December 8
2014 GERON : Announces Publication of Preclinical Data on Imetelstat Activity in Acut..
2014 GERON : to Present at the 26th Annual Piper Jaffray Healthcare Conference
2014 GERON : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
More news
Sector news Bio Therapeutic Drugs
06:14a PHARMACYCLICS : Johnson & Johnson: U.S. FDA Approves IMBRUVICA (ibrutinib) for t..
01/29DJValeant to Buy Prostate-Cancer Drug From Dendreon
01/29DJValeant in Deal to Buy Prostate-Cancer Drug Provenge From Dendreon
Plus d'actualités du secteur Bio Therapeutic Drugs


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF